Infinity Pharmaceuticals, Inc.INFI was up 6.6% after the company announced that the 120th patient has been enrolled in the phase II DYNAMO study. The global, open label, single arm study will evaluate the safety and efficacy of duvelisib in
Infinity (INFI) Up, Set to Get Duvelisib Milestone Payment
